White House Releases National Roadmap To Combat The Opioid Crisis

White House Releases National Roadmap To Combat The Opioid Crisis

Publication date: Nov 08, 2019

US President Donald Trump gives brief remarks on the Administration’s actions to combat the opioid .. . [+] crisis and announced $1. 8B in grants to states and cities to assist in their responses to this crisis during an event at the White House in Washington, DC, September 4, 2019.

The report itself highlights just how delayed federal government action on the crisis has been for years outlining how the annual estimated overdose deaths in America as a result of any opioid use have increase from 8,048 in 1999 to a staggering 47,092 in 2018.

Neither does the report analyze established conclusions for effective therapies to treat addiction or methods to curb opioid addiction before it starts, nor what factors contributed to the recent decrease in overdose deaths last year.

Drug Overdose Deaths in the U. S. Involving Opioids, 1999 to 2018 National Center for Health StatisticsAdditionally, there are two notable omissions in the report; analysis into big pharma’s role (such as Purdue Pharma) in catalyzing the epidemic early on through aggressive marketing of drugs like OxyContin, as well as an investigation into the effectiveness of harm reduction strategies to address the epidemic.

However, the report stops short of highlighting the effective dispersal of the drug through harm reduction campaigns nationally such as regional needle exchanges, which almost always include Narcan training, behavioral health analysis, and access to treatment for those addicted.

Concepts Keywords
Addiction Harm reduction
Behavioral Analysis Opioid use disorder
Bipartisan Morphine
Donald Trump Morphinans
Epidemic The United States
Harm Reduction RTT
JIM WATSON Psychoactive drugs
Naloxone Drugs
Narcan Opioids
Nonprofit Organization Behavioral therapies
Opioid Epidemic effective pathways
Opioid Addiction Epidemic omissions
Opioid Epidemic
Overdose Deaths
President Trump
Purdue Pharma
Social Stigma
Trump Administration
Washington DC
White House


Type Source Name
disease MESH community
disease MESH social stigma
disease MESH opioid addiction
drug DRUGBANK Naloxone
drug DRUGBANK Nonoxynol-9


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *